Zscaler, Inc. (ZS)

Theseus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 33 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $296.73, which forecasts a 5.87% increase in the stock price over the next year. The lowest target is $170 and the highest is $385.

Price Target: $296.73 (+5.87%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$170	$296.73	$300	$385
Change	-39.34%	+5.87%	+7.04%	+37.37%

* Price targets were last updated on Jul 1, 2025.

Analyst Ratings

The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	10	11	10	11	11	11
Buy	14	13	15	15	15	15
Hold	11	8	9	10	9	8
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	35	32	34	36	35	34

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Trevor Walsh JMP Securities	JMP Securities	Buy Maintains $310 → $355	Buy	Maintains	$310 → $355	+26.66%	Jul 1, 2025
Roger Boyd UBS	UBS	Strong Buy Maintains $315 → $365	Strong Buy	Maintains	$315 → $365	+30.23%	Jun 27, 2025
Brian Essex JP Morgan	JP Morgan	Buy Maintains $292 → $348	Buy	Maintains	$292 → $348	+24.17%	Jun 16, 2025
Andrew Nowinski Wells Fargo	Wells Fargo	Hold → Buy Upgrades $260 → $385	Hold → Buy	Upgrades	$260 → $385	+37.37%	Jun 13, 2025
Jonathan Ruykhaver Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $290 → $340	Buy	Maintains	$290 → $340	+21.31%	Jun 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.74B

Increased by 26.35%

from 2.17B

Revenue Next Year

3.30B

Increased by 20.48%

from 2.74B

EPS This Year

3.29

from -0.39

EPS Next Year

3.77

Increased by 14.78%

from 3.29

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jul 31, 2020	Jul 31, 2021	Jul 31, 2022	Jul 31, 2023	Jul 31, 2024	Jul 31, 2025	Jul 31, 2026	Jul 31, 2027
Revenue	431.27M	673.10M	1.09B	1.62B	2.17B	2.74B	3.30B	3.96B
Revenue Growth	42.41%	56.07%	62.08%	48.22%	34.07%	26.35%	20.48%	19.85%
EPS	-0.89	-1.93	-2.77	-1.40	-0.39	3.29	3.77	4.59
EPS Growth	-	-	-	-	-	-	14.78%	21.55%
Forward PE	-	-	-	-	-	85.26	74.29	61.11
No. Analysts	-	-	-	-	-	50	50	34

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	2.8B	3.5B	4.2B
Avg	2.7B	3.3B	4.0B
Low	2.5B	3.1B	3.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	29.5%	26.8%	28.4%
Avg	26.4%	20.5%	19.8%
Low	16.8%	12.3%	8.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	3.42	4.45	5.46
Avg	3.29	3.77	4.59
Low	3.12	2.91	3.98

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	35.4%	44.7%
Avg	-	14.8%	21.6%
Low	-	-11.5%	5.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.